Clinical Lymphoma Myeloma & Leukemia

Article	Citations
OA-27 Para-Medullary (PMD) and Extra-Medullary (EMD) Myeloma Demonstrate Increased Copy Number Aberration, Mutational Burden, Structural Variants and Genomic Complexity Compared to Marrow-Based Myelom	59
P-012 Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma	46
P-113 An Artificial Intelligence-Based 3D-Segmentation Assessment of Sarcopenia Utilizing Whole-Body Computed Tomography in Patients With Multiple Myeloma	36
P-068 Developing Novel DKK1-A2 CAR-T Cell Therapy for Myeloma and Other Hematologic Malignancies	36
P-112 Fall Risk Assessment and Fall Prevention in Patients With Multiple Myeloma: First Results of the MYFALL-Trial	34
P-154 Multidisciplinary, Patient-Centric Bone Disease Management in Multiple Myeloma – a Single-Centre Experience	32
P-186 Identifying a New Risk-Stratification Strategy by Including Single-Cell Biomarkers in Multiple Myeloma	30
P-202 Risk Factors Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with Front-Line VRD Regimen	30
P-314 Daratumumab for Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin G Deposits and Severe Chronic Kidney Disease	28
P-330 Stem Cell Mobilization Strategy With Pegilgrastim for Stem Cell Transplantation for Multiple Myeloma: A Direct Cost Comparison	28
P-309 Diagnostic Challenges in Systemic Amyloidosis: Exploring the Impact of Mass Spectrometry in a Middle-Income Country Cohort	27
P-232 Comprehensive Genomic Sequencing Predicts Sub-Optimal Response to Bispecific Antibodies (BsAb) and Chimeric Antigen Receptor T Cells (CAR-T) in Multiple Myeloma (MM)	27
P-342 Impact of Achieving <VGPR With Dara-RVD Induction Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients	25
MM-508 Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update	24
Poster: CT-195 Predictive Value of ST2, REG3a, and MAGIC Algorithm in Haploidentical Transplantation With Post-Transplant Cyclophosphamide Outcomes	22
Poster: CT-329 CD19-Directed Chimeric Antigen Receptor T Cell Therapy in Waldenström Macroglobulinemia: Initial Experience in Two Clinical Trials	22
Poster: AML-295: Clinical Characteristics and Outcome of Acute Leukemia in Lebanese Patients: A Retrospective Observational Analysis	21
Poster: CT-227 Dual CAR-Engineered NK92 Cells: An Off-the-Shelf Cell Therapy for Cancer	21
POSTER: MDS-156 Pyrimethamine Shows Synergy and Efficacy in Combination With Venetoclax in Preclinical Models of Therapy Resistant MDS/AML	20
AML-156 Early Deaths in Patients With Newly Diagnosed Acute Promyelocytic Leukemia: A Single-Center Retrospective Study From a General Hospital	20
ALL-004 Philadelphia Chromosome-Positive T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: A Rare Case Report	19
MCL-179 TP53 Gene Mutations in Russian Patients With Mantle Cell Lymphoma (MCL)	19
New Targetable Pathways in Chronic Lymphocytic Leukemia (CLL)	19
POSTER: AML-331 Utility of Echocardiogram in Neutropenic Patients With Gram Positive Bacteremia – A Retrospective Study	19
Poster: TCL-084 Subcutaneous Panniculitis-Like T-Cell Lymphoma With Co-Existing Lupus Panniculitis: A Case Report	19

MM-125 Adipose Tissue Metabolic Activity in Multiple Myeloma	18
P-213: A matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone for relapsed multiple myeloma	18
Poster: MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience	17
POSTER: AML-132 QuANTUM-First Trial: FLT3–Internal Tandem Duplication (FLT3-ITD)–Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS)	17
Poster: CT-132 Outcome of Sex-Mismatched Allogeneic Hemopoietic Stem Cell Transplantation from Human Leukocyte Antigen–Identical Sibling Donors in Patients With Hematologic Diseases	17
MM-341 Clinical Characteristics and Risk of Progression in Patients With Monoclonal Gammopathy of Uncertain Significance (MGUS): Long-Term Experience in a Single Tertiary Hospital	17
Poster: MM-474 Minimal Residual Disease Perception and Utilization in Real-World Multiple Myeloma Treatment	16
ABCL-289: Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After T	15
CT-009 Prognostic Role of Lymphocyte to Monocyte Ratio in PTS Treated With CAR-T for Aggressive Lymphoma	15
MM-369 Clinical Diversity of Multiple Myeloma Over Time, From First Presentation to Diagnosis, in Kurdistan Region, Iraq	15
POSTER: AML-369 Outpatient-Based Low-intensity Induction With Sorafenib in FLT3-ITD-Mutated Newly Diagnosed Acute Myeloid Leukemia (AML)	15
MM-459 Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis	15
CML-062 Define the Vulnerable - Social Determinants of Health Impact on Hematological Malignancies Affecting Children, Adolescents, and Young Adults: Systematic Review and Meta-Analysis	15
MM-530 Interventions and Outcomes of Multiple Myeloma Patients Progressing after BCMA-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy	15
ABCL-181 Germinal Center Double Hit Diffuse Large B-Cell Lymphoma Refractory to Chemoimmunotherapy: A Case Report	14
P-103: Profiling the myeloma cell surface proteome reveals CCR10 as a potential immunotherapeutic target	14
Poster: MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood	14
ABCL-269 Secondary Central Nervous System (CNS) Involvement in Diffuse Large B Cell Lymphoma (DLBCL): Ten-Year Outcomes From Mexico's National Cancer Institute	14
Is Maintenance Therapy Necessary in AML?	14
POSTER: ALL-020 Localized and Generalized Lymphadenopathy Referred to 3 Tertiary Pediatric Centers Over 6 Years: The Alarming Signs	14
Poster: ABCL-523 Immunohistochemical (IHC) Expression of Epigenetic Regulators (EZH-2 and H3K27) as well as Cell Cycle Regulators (P16, P53 and RB) in Patients Diagnosed With Primary Diffuse Large B-C	14
POSTER: AML-112 Impact of Consolidation Chemotherapy Intensity Before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia	14
ALL-071: A Phase 4 Study to Evaluate Outpatient Blinatumomab in Patients with Minimal/Measurable Residual Disease (MRD) Positivity (+) of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)	13
P-206: Antibodies to omicron variants are maintained in newly diagnosed MM patients on lenalidomide, cyclophosphamide, bortezomib and dexamethasone (RCyBorD): results from the UK RADAR/Myeloma XV Tria	13
P-212: Quantifying the average treatment effect of single vs. tandem autologous stem cell transplantation in newly diagnosed multiple myeloma using causal inference	13
P-099: Perturbation of CDK7 and super-enhancer driven transcriptional programs synergistically halts multiple myeloma cell proliferation	13
ALL-113: Pattern, Risk Factors, and Outcome Predictors of Posterior Reversible Encephalopathy Syndrome in Pediatric Cancer Patients	13
AML-214: Case Report: A Rare Case Presentation and Detection of Acute Promyelocytic Leukemia	13
AML-013 Differences in Length of Stay Between De novo Diagnosed and Transferred Patients With Acute Myeloid Leukemia in a Community Hospital	13
AML-053 Assessment of Minimal Residual Disease in Patients With Adult Acute Myeloid Leukemia: Single Egyptian Center Experience	13
Poster: CML-252: Current Patient Management and Outcomes of Chronic Myeloid Leukemia (CML) in Colombia: On Behalf of ACHO’s RENEHOC Investigators	13
Poster: MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥ 12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myel	12
P-097: A novel anti-BCMA lipid-based nanoparticle for multiple myeloma therapy	12
P-141: Prognostic impact of CD3/CD34 ratio in apheresis collection in multiple myeloma patients undergoing autologous stem cell transplant	12
CML-417: ASCEMBL Phase 3 Health-Related Quality of Life (HRQL) Comparison of Asciminib and Bosutinib for Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2	12
Poster: MM-250: Pomalidomide in Relapse / Refractory Patients with Multiple Myeloma: A Newly Adopted Approach in Ukraine	12
Poster: IBCL-034: Hairy Cell Leukemia: Single-Center Experience	12
P-100: Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma	12
AML-446 Time to Resolution of Myelosuppression and Associated Hospitalization in Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML) Treated With Ivosidenib (IVO) + Azacitidine (AZA) Compared t	12
AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program	12
Poster: MCL-041: Outcomes for Recurrent Mantle Cell Lymphoma Post-BTK Inhibitor Therapy in Japan: An Administrative Database Study	12
Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studie	12
MDS-556 Comparison of Demographics, Disease Characteristics and Outcomes Between Black and White Patients With Myelodysplastic Syndrome: A Population-Based Study	12
MDS-370: Treatments and Outcomes for Patients with Myelodysplastic Syndromes (MDS) by Revised International Prognostic Scoring System (IPSS-R) Scores at the Huntsman Cancer Institute (HCI)	12
EXABS-147-AML How Do We Overcome Resistance to Venetoclax	11
AML-271 Acute Stroke Secondary to Patent Foramen Ovale (PFO) in Patients With Acute Myeloid Leukemia (AML)	11
TCL-306 Application of the Proposed Immunohistochemistry Algorithm for the Prognostication of GATA3 and TBX21 Subtypes of Peripheral T-Cell Lymphoma, Not Otherwise Specified	11
Poster: HL-444: Autoimmune Lymphoproliferative Syndrome: A Case Presentation	11
CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)	11
EXABS-161-MPN Management of Pre-Fibrotic Primary Myelofibrosis	11

Poster: MPN-304: Identification of the Key Genes and Molecular Pathways in Essential Thrombocythemia Associated with JAK2V617F Mutation Using Bioinformatics Approach	11
P-455 Survey of multiple myeloma (MM) patients and healthcare professionals (HCPs) on the relevance of existing health quality-of-life (QoL) questionnaires (QoLQ) to real-world QoL issues of MM patien	11
Poster: MPN-110: Exosomes in Polycythemia Vera: “Mini Platelets” With Oncogenic and Thrombogenic Potential	11
EXABS-134-ALL Dual CAR T-Cell for ALL	11
P-247: Addressing the knowledge gap to optimize treatment sequencing for patients with relapsed/refractory multiple myeloma	11
Poster: MPN-433: Outcomes of COVID-19 in Hematopoietic Stem Cell Transplant Recipients: A Single-Institution, Observational Study	11
Poster: HL-049: Clinical Relevance of NKT Cells and Soluble MIC-A in Hodgkin Lymphoma	11
MPN-307 Systemic AA Amyloidosis as a Complication of Idiopathic Multicentric Castleman's Disease	10
MM-597 Diarrhea in Multiple Myeloma Autologous Stem Cell Transplant Recipients: Think Beyond Mucositis	10
MM-731 Prognostic Implications of Immune Paralysis in Newly Diagnosed Multiple Myeloma	10
Therapeutic Efficacy of Acupuncture Combined With Pharmacology in Bortezomib-Induced Peripheral Neuropathy	10
Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study	10
Subject Index	10
MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia	10
Utility of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma Patients – A Single Institution Experience From Pakistan	10
Evaluating the Impact of an Electronic Medical Record (EMR) Alert on Appropriate Dosing of Luspatercept in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Community Oncology Network	10
Barriers to Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Insights From a Large-Scale Multicenter Observational Study	10
Frequency of Practice-Changing Findings Identified by Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies	10
MPN-153 A Phase 1b Trial of DISC-0974, an Antihemojuvelin Antibody, in Participants With Myelofibrosis and Anemia	10
Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome- A Systematic Review	10
MM-418: Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Pomalidomide-Based Treatment	10
OAB-011: Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single cell level	10
MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Pati	10
Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients	10
Management Challenges in Patients with Treatment-Free Remission of Chronic Myeloid Leukemia	10
ALL-441 Outcome of Adult Acute Lymphoblastic Leukemia, a Single-Center Experience	10
ABCL-440 Preliminary Safety and Efficacy Data of Combination Polatuzumab Vedotin Rituximab, Cyclophosphamide Adriamycin, Prednisone (Pola-R-CHP) in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)	10
Demographic Characteristics of Hospitalized Patients With History of Multiple Myeloma in Remission: Insights From National Inpatient Sample 2021	10
CT-423: Neuropsychiatric Disorders in Hospitalized Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma	10
POSTER: ALL-553 Unexplained Increase in Incidence of T-Acute Lymphoblastic Leukemia/Lymphoma in Armenia	10
IBCL-381 Studying the Impact of CD38 Expression on Extracellular Adenosine and Its Connection With the PD1/PDL1 Axis in Mature B-Cell Lymphoma Patients	10
CT-244 Updated Clinical Progress of IL-10 expressing CD19 CAR-T Cells for Treatment of Relapsed or Refractory B-Cell Hematological Malignancies at Tiny Doses	10
CML-627 Concomitant Acid-Reducing Agents With TKI Increases Time to Achieve Remission in Patients With CML: A Real-World Analysis of a US Claims Database	9
CT-175 The Impact of Diabetes Mellitus on Hematopoietic Stem Cell Mobilization	9
Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?	9
Association Between Hemoglobin Improvement and Patient-Reported Outcomes in Patients With Myelofibrosis and Anemia: Post Hoc Pooled Analysis of Momelotinib Phase 3 Trials	9
POSTER: ABCL-039 Metformin in Combination With the Standard Therapy in Patients With Diffuse Large B-Cell Lymphoma: A Randomized Phase II Clinical Trial	9
Dose-Adjusted Melphalan Yields Comparable MRD-Negativity to Full-Dose Melphalan in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant	9
CLL-656 Multiplex ligation-dependent probe amplification (MLPA): Utility as a first line screening tool for detection of clinically relevant genomic aberrations in CLL	9
Limited Toxicity and Impressive Outcomes of Upfront Flag-Based Induction in Newly Diagnosed Acute Myeloid Leukemia: An Indian Scenario	9
Higher Relapse Rate and Resource Utilization With Ara-C Consolidation Chemotherapy Alone Compared With Hematopoietic Cell Transplantation in First Remission in a Cohort of Younger Adults With Acute My	9
Outcomes of Bone Marrow Transplant in ESRD vs Non-ESRD Patients: A Nationwide Analysis	9
Influence of Heart Failure Upon Incidence Rates of Pneumonia, Acute Respiratory Failure, Sepsis and Septic Shock in Patients With Polycythemia Vera	9
Time-Dependent Transfusion Status as an Independent Predictor of Overall Survival: A Post Hoc Analysis of 3 Phase 3 Trials	9
CML-674 Molecular Screening of Tyrosine Kinase Inhibitor Resistance in Tunisian Patients With Chronic Myeloid Leukemia	9
Olutasidenib Demonstrates Promising Tolerability and Efficacy in IDH1-Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms	9
MM-645 Updated OS of Patients With AL Amyloidosis After CAEL-101	9
Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohor	9
POSTER: ABCL-222 Diffuse Large Cell Lymphoma of the Uterus Presented With Vaginal Bleeding: A Case Report	9
MDS-304 Disparities in Myelodysplastic Syndromes Mortality Among Older Adults in the United States: A CDC WONDER Database Analysis	9
POSTER: HL-281 Treatment of Relapsed Hodgkin Lymphoma With Pembrolizumab as Monotherapy	8
POSTER: ABCL-142 Efficacy and Safety of Single-Agent Blinatumomab as Salvage Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia (B-ALL): Real-Life Experience	8
POSTER: TCL-154 STAT3 Mutations are Associated With Differential Treatment Responses to Methotrexate and Cyclophosphamide in T-Large Granular Lymphocyte Leukemia	8
POSTER: AML-260 A Metabolically Optimized, Non-Cytotoxic Low-Dose Weekly Decitabine/Venetoclax Regimen in MDS and AML	8
POSTER: MPN-498 Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation an	8
IBCL-297 Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL)	8
CLL-240 Frequency of IKZF3 L162R Mutation in B-Cell Lymphoproliferative Disorders	8
OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multipl	8
P-001: RNA-sequencing reveals transcriptomic similarity of AL amyloidosis and MGUS aberrant plasma cells along with several potential ALA target candidate genes	8
P-139 Impact of melphalan staggered dosing prior to autologous hematopoietic cell transplantation for multiple myeloma patients	8
OA-38 Physical activity interventions to improve functional performance in patients with multiple myeloma	8
CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia	8
POSTER: MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia	8
SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?	8
POSTER: HL-603 Hodgkin Lymphoma in Tripoli University Hospital Libya	8
P-100 Prevalence of monoclonal gammopathies in adult Uruguayan population	8
POSTER: TCL-196 Hepatosplenic T-Cell Lymphoma in Adolescents and Young Adults: A Case Report	8
OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)	8
P-020: PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer	8
P-019: Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma patients treated with idecabtagene vicleucel (ide-ce	8
Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome	8
OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RR	7
P-309 ZnDDC, a novel CELMoD-like agent binding to DDB1-CRBN complex demonstrates significant synergism with BTZ and IMiDs and overcomes IMiDs resistance in myeloma cell lines and primary samples	7
P-361 Genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma	7
P-266 Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma	7
POSTER: MPN-193 Incidence of Blast Phase in Myelofibrosis According to Anemia Severity	7
AML-327 Novel Anti–B7-H3 Blocking Antibody Enhances NK Cell–Mediated Cytotoxicity and Improves Outcomes in AML-Bearing Mice	7
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma	7
OA-08 GPRC5D-targeted CAR-T cell therapy in patients with relapsed or refractory multiple myeloma progressing after or refractory to BCMA CAR-T cell therapy: updated eesults from a phase 2 clinical tr	7
P-383 A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies	7

MM-169: ANCHOR (OP-104): Melflufen Plus Dexamethasone and Bortezomib in Relapsed/Refractory Multiple Myeloma (RRMM)—Optimal Dose, Updated Efficacy and Safety Results	7
OAB-037: Assessing the prognostic utility of the Mayo 2018 and IMWG 2020 smoldering multiple myeloma risk stratification scores applied post diagnosis	7
POSTER: CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies	7
POSTER: CT-127 Evaluation of Cytomegalovirus Infection/Disease Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience	7
OA-22 TiMMing: developing an innovative suite of bioinformatic tools to harmonize and track the origin of copy number alterations in the evolutionary history of multiple myeloma	7
AML-194 Second Hematological Malignancies in Survivors of Breast Cancer: An Indian Institutional Analysis	7
Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no	7
ALL-606 A Comprehensive Retrospective Analysis of Cases from 2020-2022 in Children With Relapsed Acute Leukemia: Temporal Trends and Clinical Characteristics	7
P-378 Longitudinal antibody and T-cell kinetics over four doses of COVID-19 vaccination and predictors of poor response in patients with multiple myeloma	7
Poster: CLL-517 Hypertension as an Adverse Event of Ibrutinib: Does Age Matter?	7
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study	7
P-200 MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism	7
POSTER: MDS-145 A Successful Treatment of Relapsed/Refractory MDS Patient who is Followed Under Hemodialysis	7
POSTER: MPN-183 Interferon Treatment Suppresses In Vitro NETosis in Neutrophils Derived from Patients With Myeloproliferative Neoplasms	7
Editorial Board	7
P-278 Estimating the size of patients with relapsed/ refractory multiple myeloma treated with 1-3 and 4 or more prior lines of therapy in the United States	7
POSTER: MM-638 Role of the Combination of FDG-PET plus Whole Body MRI for Staging Newly Diagnosed and Relapsed/Refractory Multiple Myeloma (MM): A Prospective Trial	7
SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia	7
Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group	6
Treatment patterns, efficacy, and tolerability of belantamab mafodotin in patients with relapsed and/or refractory multiple myeloma: a real-world analysis	6
OA-14 Prospective Functional Bone Disease Evaluation of Newly Diagnosed Multiple Myeloma with Combined Use of (18)F-FDG-PET/CT and Whole-Body Diffusion Weighted Magnetic Resonance	6
P-430 Incidence of primary plasma cell leukemia with the new diagnostic criteria	6
Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed Therapy	6
Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospec	6
Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates	6
Neurolymphomatosis: An Unusual Manifestation of Relapsed/Refractory Lymphoma	6
Management of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoiesis-Stimulating Agent (ESA) Treatment	6
Association Of -308G/A, -238G/A TNF-α Polymorphisms with Multiple Myeloma Risk and Survival: A Systematic Review and Meta-Analysis	6
Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era	6
POSTER: ABCL-152 Evaluation of Safety Profile of Rituximab + Lenalidomide Protocol in Frail Elderly Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients	6
Safety, Feasibility, and Efficacy of Exercise Interventions for People With Multiple Myeloma: A Systematic Review	6
Impact of Facility Type on Survival in Chronic Myelomonocytic Leukemia: A Propensity Score Matched, National Cancer Database Analysis	6
Recent Advances in the Use of Chimeric Antigen Receptor–Expressing T-Cell Therapies for Treatment of Multiple Myeloma	6
SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia	6
Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial	6
Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival	6
P-067 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma	6
Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	6
MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera	6
IBCL-541 A Comprehensive Single-Cell Multi-Omic Analysis to Depict the Biological Heterogeneity of Follicular and Large B-Cell Lymphomas	6
Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival	6
A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia	6
Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facili	6
POSTER: ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy	6
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial	6
MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)	6
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Old	6
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies	6
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma	6
Epidemiological Profile and Outcomes of Patients Admitted to the Intensive Care Unit at Yeolyan Hematology and Oncology Center: A Retrospective Study	6
MDS-570 NPM1-Mutated Myeloid Neoplasms Irrespective of Blast Count Are Associated With Better Outcomes With Acute Myeloid Leukemia Treatment Approach	6
Table of Contents	6
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study	6
P-138 Real World Single Centre Experience On The Use of Radiotherapy In The Treatment of Patients with Multiple Myeloma	6
Prognostic Value of Dynamic Measurable Residual Disease Monitoring by Multiflowcytometry in Elderly Patients With Nonintensively Treated Acute Myeloid Leukemia	6
P-287 Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma in real life context in France: IMAGE subgroup analysis based on subgroups of interest	5
CLL-020 Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies	5
POSTER: CLL-347 Venetoclax Therapy in Chronic Lymphocytic Leukemia Patients Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation	5
HL-447 Lymphoma Diagnosis Delay: Biopsy Strategy Insights	5
P-373 Functional genomics of genes residing in the minimally deleted chromosome 17p13 region in multiple myeloma: therapeutic implications	5
AML-385 A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)	5
XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib With Potential Implications for Its Clinical Use	5
AML-728 Clinical, Molecular, and Treatment Characteristics of Long-Term Survivors Amongst Older Adults with IDH1/2-Mutated Acute Myeloid Leukemia Treated with IDH Inhibitors	5
Changes in the Metabolome of Serum and Cerebrospinal Fluid During Intensive Treatment of Acute Lymphoblastic Leukemia in Children	5
ABCL-370 Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T-Cell Therapy in the	5
ALL-434 Xeroderma Pigmentosum and Acute Lymphoblastic Leukemia: Case Report	5
Impact of Acute Heart Failure in Chronic Myeloid Leukemia (CML): Propensity-Matched Analysis of National Inpatient Sample	5
POSTER: CT-085 Assessment of Prognostic Factors, Colonization, and Infection Epidemiology in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	5
Bone Marrow Necrosis in APML	5
ALL-259 Clinical and Molecular Features of Pediatric BCP-ALL With TSLP Receptor (CRLF2) Expression	5
Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After ≥2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II	5
MM-241 Management and Outcomes of Anti-CD38 Refractory Multiple Myeloma: Recycling of Therapies and Impact of PFS on Subsequent Treatments	5
Hyper-CVAD in 2021: Lessons Learned and New Approaches	5
Poster: CT-118: PH3 Study of Efficacy and Safety of Iptacopan (LNP023), an Oral Complement Factor B Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia Despite Anti-C5	5
Acute Myeloid Leukemia and Nonseminomatous Germ Cell Tumor in a Patient With Klinefelter Syndrome	5
CLL-492 Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	5
CML-455 Management Challenges in Patients with Treatment-Free Remission of Chronic Myeloid Leukemia	5
AML-750 Global Burden and Trends in Acute Myeloid Leukemia in the European Union From 1990 to 2021: Insights from the Global Burden of Disease Study, 2021	5
Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome–Positive Acute Lympho	5
Low MS4A3 Expression Inhibits Differentiation of HSPCs in Patients With Myelodysplastic Syndromes	5
HL-577 Assessment of Venous Thromboembolism Risk in Patients With Hodgkin Lymphoma	5
P-333 Multi-omic analysis of multiple myeloma subtypes reveals epigenetic programs of high-risk disease	5
Management Algorithm for Nodular Lymphocyte-Predominant Hodgkin Lymphoma	5
POSTER: MCL-155 Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of	5
TCL-246 Peripheral T-Cell Lymphoma (PTCL) and treatment out-come Single centre retrospective study	5
Poster: MM-451 Treatment Patterns Among Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population	5
MM-714 Epidemiological Differences in Young-Onset Multiple Myeloma Between a Developed and Developing Country: An Epidemiological Study Using the Jordan Cancer Registry and the SEER Database From 2009	5
International Expansion of Modern AML Therapy	5
IBCL-080 Single Egyptian Oncology Center Experience in Lymphoplasmacytic Lymphoma (LPL)	5
Prognostic Value of EASIX Score in Allogeneic Hematopoietic Stem Cell Transplantation	5
Mantle Cell Lymphoma Presenting as Bullous Pemphigoid: A Rare Paraneoplastic Syndrome	5
Next Questions in Aggressive B-cell Lymphomas	5
P-079: IL10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in Multiple Myeloma	5
POSTER: CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With	5
CT-114 Infectious Complications in Patients With Hematologic Malignancies Receiving CD19 vs. BCMA Targeted CAR-T Therapy	5